Paper Details

  1. Home
  2. Paper Details

Double-blind, placebo-controlled trial comparing long-term suppressive with short-term oral acyclovir therapy for management of recurrent genital herpes.

Author: Bailey-FarchioneA, BenedettiJ, BolgianoD, CoreyL, DavisL G, MattisonH R, ReichmanR C, RemingtonM, WinterC

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the effectiveness of three treatments for 156 patients with frequent genital herpes outbreaks: daily acyclovir, intermittent acyclovir, and placebo. The study found that daily acyclovir was significantly more effective than both intermittent acyclovir and placebo in reducing the frequency and duration of outbreaks. The average number of days per month with outbreaks was 0.32 for the daily acyclovir group, compared to 4.18 for the intermittent group and 4.72 for the placebo group. The study concludes that daily acyclovir is the most effective treatment for patients with frequent genital herpes outbreaks.
Paper Details　
Original Abstract of the Article :
A total of 156 patients with frequently recurring genital herpes were enrolled in a randomized, double-blind, one-year trial comparing long-term suppressive and intermittent oral acyclovir therapy with placebo in the management of recurrent genital herpes. Subjects received either suppressive treatm...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/3044086

データ提供：米国国立医学図書館（NLM）

Acyclovir for Recurrent Genital Herpes: Long-Term vs. Short-Term Therapy

Recurrent genital herpes, a common and often distressing condition, can disrupt daily life. This study compares the effectiveness of long-term suppressive acyclovir therapy with short-term intermittent therapy in managing recurrent genital herpes.

Long-Term Suppression: A More Effective Approach

The researchers found that long-term suppressive acyclovir therapy was superior to intermittent therapy in reducing the frequency and duration of herpes outbreaks. This suggests that daily acyclovir can provide more consistent protection against herpes recurrences. Imagine a desert traveler with a reliable camel, providing steady transportation and protection from the harsh environment. Long-term suppressive acyclovir therapy offers a similar level of consistent protection against recurrent herpes.

Managing Herpes Recurrences: Finding the Right Balance

This research highlights the potential benefits of long-term suppressive therapy for recurrent genital herpes. By taking acyclovir daily, individuals can reduce the frequency and duration of outbreaks, potentially improving their quality of life. This approach, like a careful traveler planning their desert journey, aims to minimize the impact of herpes outbreaks and ensure a smoother and more comfortable experience.

Dr. Camel's Conclusion

This study highlights the effectiveness of long-term suppressive acyclovir therapy in managing recurrent genital herpes. The findings suggest that daily acyclovir can significantly reduce the frequency and duration of outbreaks, providing more consistent protection and potentially improving quality of life.
Date :
  1. Date Completed 1988-09-22
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

3044086

DOI: Digital Object Identifier

3044086

Related Literature

Article Analysis
・Effective treatment of genital herpes
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.